Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | OSU-T315 |
| Trade Name | |
| Synonyms | OSUT315|OSU T315 |
| Drug Descriptions |
OSU-T315 is an ILK inhibitor potentially inhibiting Akt signaling and inducing tumor cell cytotoxicity (PMID: 32439931, PMID: 25293770). |
| DrugClasses | |
| CAS Registry Number | 2070015-22-2 |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ARQ 751 + OSU-T315 | ARQ 751 OSU-T315 | 1 | 0 |
| GSK690693 + OSU-T315 | GSK690693 OSU-T315 | 1 | 0 |
| Ipatasertib + OSU-T315 | Ipatasertib OSU-T315 | 2 | 0 |
| Miransertib + OSU-T315 | Miransertib OSU-T315 | 2 | 0 |
| MK2206 + OSU-T315 | MK2206 OSU-T315 | 1 | 0 |
| OSU-T315 | OSU-T315 | 0 | 0 |